DK3185872T3 - Formulering af testosteron og metoder til behandling hermed - Google Patents
Formulering af testosteron og metoder til behandling hermed Download PDFInfo
- Publication number
- DK3185872T3 DK3185872T3 DK15834874.8T DK15834874T DK3185872T3 DK 3185872 T3 DK3185872 T3 DK 3185872T3 DK 15834874 T DK15834874 T DK 15834874T DK 3185872 T3 DK3185872 T3 DK 3185872T3
- Authority
- DK
- Denmark
- Prior art keywords
- testosterone
- formulation
- treatment
- methods
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960003604 testosterone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043277P | 2014-08-28 | 2014-08-28 | |
| PCT/US2015/047385 WO2016033430A1 (en) | 2014-08-28 | 2015-08-28 | Formulations of testosterone and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3185872T3 true DK3185872T3 (da) | 2021-06-21 |
Family
ID=55400639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15834874.8T DK3185872T3 (da) | 2014-08-28 | 2015-08-28 | Formulering af testosteron og metoder til behandling hermed |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10258631B2 (da) |
| EP (1) | EP3185872B1 (da) |
| KR (1) | KR102514657B1 (da) |
| CN (1) | CN106922128B (da) |
| CA (1) | CA2958696C (da) |
| DK (1) | DK3185872T3 (da) |
| ES (1) | ES2877107T3 (da) |
| WO (1) | WO2016033430A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2930658T3 (es) | 2005-04-15 | 2022-12-20 | Tolmar Inc | Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| EP3185872B1 (en) | 2014-08-28 | 2021-03-31 | Board of Regents, The University of Texas System | Formulations of testosterone and methods of treatment therewith |
| KR102351762B1 (ko) * | 2016-03-02 | 2022-01-18 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 테스토스테론 제형 및 이를 이용한 치료 방법 |
| KR101981790B1 (ko) | 2017-04-07 | 2019-05-27 | 주식회사 종근당바이오 | 실크 피브로인으로 코팅되어 장내 정착성이 향상된 유산균을 포함하는 조성물 |
| AU2019396139A1 (en) * | 2018-12-14 | 2021-07-15 | Acerus Biopharma Inc. | Active ester derivatives of testosterone, compositions and uses thereof |
| KR102009732B1 (ko) | 2019-04-15 | 2019-08-12 | 주식회사 쎌바이오텍 | 세포 농축 방법에 의한 이중코팅 유산균의 제조방법 |
| KR102009731B1 (ko) | 2019-04-15 | 2019-08-12 | 주식회사 쎌바이오텍 | 단백질 가수분해물을 이용한 단백질-다당류 이중코팅 유산균의 제조방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663583A (en) | 1970-03-30 | 1972-05-16 | Whitestone Chemical Corp | Partially saponified ethoxylated triglycerides of ricinoleic acid |
| US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
| CN1062129C (zh) | 1995-09-14 | 2001-02-21 | 徐荣祥 | 药物基质及其用途 |
| AU6265998A (en) | 1997-02-07 | 1998-08-26 | Theratech, Inc. | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
| AU5486899A (en) * | 1998-08-13 | 2000-03-06 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
| US7029657B2 (en) | 2002-08-02 | 2006-04-18 | Balance Pharmaceuticals, Inc. | Nasal spray steroid formulation and method |
| US20040126448A1 (en) | 2002-08-05 | 2004-07-01 | Nils-Olof Lindberg | Sexual dysfunction compounds |
| DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
| ES2930658T3 (es) | 2005-04-15 | 2022-12-20 | Tolmar Inc | Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos |
| US8492369B2 (en) * | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| MX2012011952A (es) * | 2010-04-12 | 2013-02-07 | Clarus Therapeutics Inc | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. |
| MY158809A (en) | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| EP2680816A1 (en) * | 2011-03-03 | 2014-01-08 | Allergan, Inc. | Non-aqueous silicone-based ophthalmic formulations |
| US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US20130040922A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US20140227798A1 (en) * | 2011-09-30 | 2014-08-14 | Hitachi, Ltd. | Molecular Template and Method for Producing Same |
| US20130224268A1 (en) | 2012-02-27 | 2013-08-29 | Newgen Biopharma Corp. | Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same |
| WO2014076569A2 (en) | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
| EP3185872B1 (en) | 2014-08-28 | 2021-03-31 | Board of Regents, The University of Texas System | Formulations of testosterone and methods of treatment therewith |
| KR102351762B1 (ko) | 2016-03-02 | 2022-01-18 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 테스토스테론 제형 및 이를 이용한 치료 방법 |
-
2015
- 2015-08-28 EP EP15834874.8A patent/EP3185872B1/en active Active
- 2015-08-28 DK DK15834874.8T patent/DK3185872T3/da active
- 2015-08-28 WO PCT/US2015/047385 patent/WO2016033430A1/en not_active Ceased
- 2015-08-28 CA CA2958696A patent/CA2958696C/en active Active
- 2015-08-28 ES ES15834874T patent/ES2877107T3/es active Active
- 2015-08-28 US US15/507,246 patent/US10258631B2/en active Active
- 2015-08-28 CN CN201580052549.8A patent/CN106922128B/zh not_active Expired - Fee Related
- 2015-08-28 KR KR1020177008366A patent/KR102514657B1/ko active Active
-
2019
- 2019-04-12 US US16/382,607 patent/US10751348B2/en active Active
-
2020
- 2020-08-18 US US16/996,780 patent/US11844805B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102514657B1 (ko) | 2023-03-29 |
| US11844805B2 (en) | 2023-12-19 |
| EP3185872B1 (en) | 2021-03-31 |
| EP3185872A1 (en) | 2017-07-05 |
| US10258631B2 (en) | 2019-04-16 |
| US20170281644A1 (en) | 2017-10-05 |
| KR20170045326A (ko) | 2017-04-26 |
| EP3185872A4 (en) | 2018-03-07 |
| US20210030767A1 (en) | 2021-02-04 |
| ES2877107T3 (es) | 2021-11-16 |
| CA2958696C (en) | 2022-09-06 |
| CN106922128A (zh) | 2017-07-04 |
| CN106922128B (zh) | 2021-04-02 |
| BR112017003900A2 (pt) | 2017-12-05 |
| WO2016033430A1 (en) | 2016-03-03 |
| US20190298736A1 (en) | 2019-10-03 |
| US10751348B2 (en) | 2020-08-25 |
| CA2958696A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
| IL249292A0 (en) | Methods and devices for treating pulmonary edema | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| DK3153169T3 (da) | Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt | |
| IL251505A0 (en) | Neuroactive compounds and methods of use thereof | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3116511T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3812392T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| PL3200815T3 (pl) | Sposoby i kompozycje do leczenia nowotworu | |
| DK3183010T3 (da) | Anordning og tilhørende fremgangsmåde til behandling af medicinsk affald | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3178324T3 (da) | Mikrobicid og fremgangsmåde til fremstilling af samme | |
| DK3185872T3 (da) | Formulering af testosteron og metoder til behandling hermed | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme |